Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V

被引:19
作者
Rai, Shinya [1 ]
Tanaka, Hirokazu [1 ]
Suzuki, Mai [2 ]
Espinoza, J. Luis [1 ]
Kumode, Takahiro [1 ]
Tanimura, Akira [3 ]
Yokota, Takafumi [3 ]
Oritani, Kenji [4 ]
Watanabe, Toshio [5 ]
Kanakura, Yuzuru [3 ]
Matsumura, Itaru [1 ]
机构
[1] Kindai Univ, Fac Med, Dept Hematol & Rheumatol, Osaka, Japan
[2] Natl Canc Ctr, Div Hematol Malignancy, Chuo Ku, Tokyo, Japan
[3] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka, Japan
[4] Int Univ Hlth & Welf, Dept Hematol, Chiba, Japan
[5] Nara Womens Univ, Grad Sch Human & Sci, Dept Biol Sci, Nara, Nara, Japan
基金
日本学术振兴会;
关键词
C-KIT; STEM-CELL; CANCER; RECEPTOR; GENE; INHIBITORS; ENDOCYTOSIS; ACTIVATION; MUTATIONS; DOPAMINE;
D O I
10.1038/s41467-020-17666-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Mutated receptor tyrosine kinases (MT-RTKs) such as internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3 ITD) and a point mutation KIT D816V are driver mutations for acute myeloid leukemia (AML). Clathrin assembly lymphoid myeloid leukemia protein (CALM) regulates intracellular transport of RTKs, however, the precise role for MT-RTKs remains elusive. We here show that CALM knock down leads to severely impaired FLT3 ITD-or KIT D814V-dependent cell growth compared to marginal influence on wild-type FLT3- or KIT-mediated cell growth. An antipsychotic drug chlorpromazine (CPZ) suppresses the growth of primary AML samples, and human CD34(+)CD38(-) AML cells including AML initiating cells with MT-RTKs in vitro and in vivo. Mechanistically, CPZ reduces CALM protein at post transcriptional level and perturbs the intracellular localization of MT-RTKs, thereby blocking their signaling. Our study presents a therapeutic strategy for AML with MT-RTKs by altering the intracellular localization of MT-RTKs using CPZ.
引用
收藏
页数:14
相关论文
共 58 条
[1]   Therapeutic targeting of c-KIT in cancer [J].
Ashman, Leonie K. ;
Griffith, Renate .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (01) :103-115
[2]  
Ban Thomas A, 2007, Neuropsychiatr Dis Treat, V3, P495
[3]   Reduced cancer incidence among patients with schizophrenia [J].
Barak, Y ;
Achiron, A ;
Mandel, M ;
Mirecki, I ;
Aizenberg, D .
CANCER, 2005, 104 (12) :2817-2821
[4]   Endocytic control of signaling at the plasma membrane [J].
Barbieri, Elisa ;
Di Fiore, Pier Paolo ;
Sigismund, Sara .
CURRENT OPINION IN CELL BIOLOGY, 2016, 39 :21-27
[5]  
Bixby Dale, 2009, Hematology Am Soc Hematol Educ Program, P461, DOI 10.1182/asheducation-2009.1.461
[6]   A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response [J].
Brandwein, J. M. ;
Hedley, D. W. ;
Chow, S. ;
Schimmer, A. D. ;
Yee, K. W. L. ;
Schuh, A. C. ;
Gupta, V. ;
Xu, W. ;
Kamel-Reid, S. ;
Minden, M. D. .
LEUKEMIA, 2011, 25 (06) :945-952
[7]   Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study [J].
Cairoli, R ;
Beghini, A ;
Grillo, G ;
Nadali, G ;
Elice, F ;
Ripamonti, CB ;
Colapietro, P ;
Nichelatti, M ;
Pezzetti, L ;
Lunghi, M ;
Cuneo, A ;
Viola, A ;
Ferrara, F ;
Lazzarino, M ;
Rodeghiero, F ;
Pizzolo, G ;
Larizza, L ;
Morra, E .
BLOOD, 2006, 107 (09) :3463-3468
[8]   Spatial regulation of receptor tyrosine kinases in development and cancer [J].
Casaletto, Jessica B. ;
McClatchey, Andrea I. .
NATURE REVIEWS CANCER, 2012, 12 (06) :386-399
[9]   The role of CALM-AF10 gene fusion in acute leukemia [J].
Caudell, D. ;
Aplan, P. D. .
LEUKEMIA, 2008, 22 (04) :678-685
[10]   Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes [J].
Choudhary, Chunaram ;
Olsen, Jesper V. ;
Brandts, Christian ;
Cox, Jurgen ;
Reddy, Pavankurnar N. G. ;
Boehmer, Frank D. ;
Gerke, Volker ;
Schmidt-Arras, Dirk-E. ;
Berdel, Wolfgang E. ;
Mueller-Tidow, Carsten ;
Mann, Matthias ;
Serve, Hubert .
MOLECULAR CELL, 2009, 36 (02) :326-339